Navigation Links
Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Date:4/7/2008

Delivery Systems and Specific Molecular Structures Needed for siRNA

Therapeutic Success

LONDON, April 7, 2008 /PRNewswire/ -- Silence Therapeutics plc (AIM:SLN) Europe's leading RNAi-focused biotechnology company, today comments on two recent journal articles: Nature(1) "Sequence-and target-independent angiogenesis suppression by siRNA via TLR3" Mark E. Kleinman, et. al., and Molecules and Cells(2) "Immune Activation by siRNA/Liposome Complexes in Mice is Sequence-Independent: Lack of a Role for Toll-like Receptor 3," Kim et. al. In these two publications, researchers questioned current thinking on the mode of action of siRNA therapeutics suggesting that they work by mechanisms other than via specific gene silencing.

Data published in the Nature article (Kleinman et. al.) have been interpreted in recent days in the lay press as a "Setback for Some RNA-Based Drugs" (New York Times(5)). Silence Therapeutics views the cited Nature paper, and another recent paper in Molecules and Cells(2) as highlighting the need for a functional delivery system to ensure the therapeutic siRNA is able to enter cells and achieve gene silencing.

Both studies further reinforce the importance of chemically modifying siRNA to create molecular structures which do not cause unwanted immune stimulation such as cytokine release and interferon response.

The two new studies support the long-standing development approach of Silence Therapeutics, which has focused its research on developing both a potent RNAi-mediating delivery system (AtuPLEX) and chemically-modified siRNA (AtuRNAi) molecules.

Jeff Vick, CEO of Silence Therapeutics, said, "More than eight years ago, Silence Therapeutics recognized the need for, and pioneered the development of, a functional systemic RNAi delivery system that combines proprietary chemical modification and lipid technologies to achieve efficient intracellular uptake without triggering an immune s
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Spanien, September 23, 2014 ... dass sich Fernzugriffe auf eTMF im Jahr ... ermöglicht den Sponsoren von klinischen Versuchsreihen, die ... und Vollständigkeit von Stammdateien mit Informationen über ... zu erfüllen     Die bisher ...
(Date:9/22/2014)... 22, 2014 Levi & Korsinsky is investigating ... "the Company") (NasdaqGS: SIAL ) for possible ... law in connection with the sale of the Company ... to learn more about the investigation: http://zlkdocs.com/SIAL-Info-Request-Form_ma-2199 , ... to you. Under the terms of the ...
(Date:9/22/2014)... , Sept. 22, 2014 Avanir Pharmaceuticals, ... it is offering to sell $200 million of its ... Deutsche Bank Securities and BofA Merrill Lynch are acting ... grant the underwriters a 30-day option to purchase additional ... to be sold in the offering are being sold ...
Breaking Medicine Technology:Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 2Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 3Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 4Branchenweite Umfrage zeigt, dass sich Fernzugriffe auf eTMF im Jahr 2015 verdoppeln werden 5SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... S.C., Sept. 9 At approximately 3:21,PM ... Chairman and Founder of,CureHIV.us, agreed to act ... Global,Humanceuticals, Inc,s., new extremely effective, safe and ... non-government, U.S.,and foreign institutions, organizations, and corporations, ...
... Effective Antibiotics Against ,Superbugs, BOSTON, Sept. 6 ... may have discovered the path,toward developing better drugs ... resistance to common antibiotics. The,researchers have discovered a ... opens to door to new avenues of research., ...
Cached Medicine Technology:Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 2Boston University Biomedical Engineers Find Chink in Bacteria's Armor 3
(Date:9/22/2014)... September 23, 2014 Career Step, ... training, will be attending and exhibiting at the ... Health Information Management Association (AHIMA) in San Diego, ... through October 1, and Career Step will be ... suite of coding training products, including CLiM™, its ...
(Date:9/22/2014)... Fashion Footwear Association of New York (FFANY) and leading ... research to the University of Pittsburgh Cancer Institute (UPCI), ... the proceeds of the 20th annual QVC Presents "FFANY ... several cancer research centers across the country, including UPCI ... has been selected to receive funds from this year,s ...
(Date:9/22/2014)... New York, NY (PRWEB) September 22, 2014 ... Women’s Radio Network launched their first evening show, “KC After ... and Marcus Edwards, “KC After Dark” will air every Tuesday ... away a free iPad for the 50th caller, and because ... it well past the call in mark with 500 callers. ...
(Date:9/22/2014)... 2014 United States District Judge ... federal mesh lawsuits ( http://www.meshinjurylawfirm.com/lawsuits/ ) filed against ... for pretrial matters, issued an order in the ... System Products Liability Litigation (United States District Court ... no. 2:12-md-02326)—requiring that four member cases be ready ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Locating the ... industry is now easier using the Quotes Pros portal ... trying to local universal life insurance pricing from different ... coverage plans that are easily viewed when using the ... specific lengths of coverage. The plan data can be ...
Breaking Medicine News(10 mins):Health News:Career Step to Exhibit at AHIMA Convention September 27 through October 1 2Health News:Heels for a cause: FFANY, QVC Present $240,000 from shoe sales to Pitt researchers 2Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Universal Life Insurance Prices for Adults Added to National Insurer Portal Online 2
... 27 April 2009 Elsevier, the world-leading publisher ... services, is pleased to announce the launch of ... the journal on infectious disease dynamics ( http://www.elsevier.com/locate/epidemics ... papers on infectious disease dynamics in the broadest ...
... global partner and customer pilots in Europe and Asia ... Live - Booth #333- With deployments of its PLUS ... and healthcare installations in the United States, and pilots ... , a leader in precision UWB real-time location ...
... hormone-lowering therapy may require close monitoring, researchers say, ... proven effective, treating prostate cancer with the testosterone-lowering ... men,s risk for developing bone fractures and fatal ... likelihood of developing either side effect remains low, ...
... BELLEVUE, Wash., April 27 HIPAApedia.com, the first ... IT community and business professionals interested in HIPAA ... Sponsored by Edifecs, the leader in providing healthcare ... provides an online environment for collaborative, transparent, and ...
... Unique Software Application Suite for the Assessment of the ... providing state-of-the-art CT and MR imaging systems to physician ... American Urological Association that the U.S. Food and Drug ... unique software application package for the assessment of urinary ...
... today announced financial and operating results for its first quarter ended ... Quarter Summary:, , ... Net income attributable to HCA Inc. ... first quarter. , Adjusted EBITDA ...
Cached Medicine News:Health News:Elsevier launches Epidemics -- the journal on infectious disease dynamics 2Health News:Time Domain Goes Global, Announces Worldwide Availability of its PLUS(TM) Ultra Wideband Real-Time Location System Sensor Platform 2Health News:Time Domain Goes Global, Announces Worldwide Availability of its PLUS(TM) Ultra Wideband Real-Time Location System Sensor Platform 3Health News:Time Domain Goes Global, Announces Worldwide Availability of its PLUS(TM) Ultra Wideband Real-Time Location System Sensor Platform 4Health News:Heart, Bone Problems May Follow Prostate Cancer Treatment 2Health News:Heart, Bone Problems May Follow Prostate Cancer Treatment 3Health News:HIPAApedia.com Goes Live - The First Dedicated Educational Community Wiki Aimed at Healthcare Information Professionals Interested in HIPAA Regulatory Issues and Solutions. 2Health News:Neuisys Announces FDA Clearance of UroCARE 2Health News:HCA Reports First Quarter 2009 Results 2Health News:HCA Reports First Quarter 2009 Results 3Health News:HCA Reports First Quarter 2009 Results 4Health News:HCA Reports First Quarter 2009 Results 5Health News:HCA Reports First Quarter 2009 Results 6Health News:HCA Reports First Quarter 2009 Results 7Health News:HCA Reports First Quarter 2009 Results 8Health News:HCA Reports First Quarter 2009 Results 9Health News:HCA Reports First Quarter 2009 Results 10Health News:HCA Reports First Quarter 2009 Results 11Health News:HCA Reports First Quarter 2009 Results 12Health News:HCA Reports First Quarter 2009 Results 13Health News:HCA Reports First Quarter 2009 Results 14
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... Volk's super series slit ... resolution viewing of the ... fundus diagnostic capability, specifically ... of view, fundus image ...
Volk indirect lenses. General diagnosis & treatment....
Medicine Products: